A Simple Molecule with a Notorious (or Celebrated) Reputation
Chemically speaking, N,N-dimethyltryptamine—DMT for short—is a modest structure: a simple tryptamine with two methyl groups. This simplicity contrasts sharply with the outsized claims attached to it, ranging from overwhelming visions to purported encounters with “entities.” Before venturing into that slippery terrain, it is worth establishing what is actually documented, which is remarkable enough on its own: DMT is not just a compound found out in the wild, but one our own bodies know how to make.
DMT Across the Biosphere
DMT occurs across a remarkable variety of living organisms: plants, seeds, barks, roots, fungi, and even mammalian and amphibian tissues. Chemist Alexander Shulgin dedicated an entire chapter of TiHKAL to it titled, precisely, “DMT is Everywhere,” emphasizing the compound’s ubiquity. Yet that “everywhere” warrants a level-headed reading: being present does not mean being present in significant amounts, nor does it mean it serves the same biological function in every organism. Where it has undeniably played an enduring cultural role is in specific South American plants, woven into ritual practices for centuries.
First European Accounts: The 19th-Century Amazon
In the mid-19th century, explorers such as English botanist Richard Spruce and, earlier, German naturalist Alexander von Humboldt documented the use of psychoactive preparations by Indigenous peoples. These snuffs and brews—known by names such as yopo, epená, or jurema—were administered in very high doses and, in some cases, blown into the nostrils through a pipe by an assistant. Chroniclers described abrupt, intense states accompanied by pronounced physical discomfort, recording accounts of visions, out-of-body sensations, and purported contact with ancestors.
Alongside these was another preparation, consumed as a beverage with more gradual effects: ayahuasca or yagé, associated with a rich iconography that we might call, somewhat anachronistically, “psychedelic art.” While valuable as historical records, these accounts were filtered through the colonial gaze of their authors; they should be read as period chronicles rather than neutral descriptions.
Manske: The Synthesis That Slept in a Drawer
While those botanical specimens sat archived in European museums, Canadian chemist Richard Manske synthesized the molecule we now call DMT in 1931 through an independent pathway, entirely unrelated to those plants. He recorded its structure and filed it away. At the time, nobody suspected that this compound was identical to the active constituent in Amazonian preparations, that it had psychoactive effects, or that the human body produced it. Scientific interest would take another two decades to awaken.
The 1950s Turning Point: Tryptamines Under the Microscope
In the early 1950s, the discovery of LSD and the characterization of serotonin shook the foundations of psychiatry and helped lay the groundwork for modern neuroscience. Researchers—who began referring to themselves as “psychopharmacologists”—rushed to isolate the active compounds from the plants described a century earlier. The tryptamine family became an obvious focal point: both LSD and serotonin belong, in a broad sense, to this chemical lineage.
Stefan Szára: Self-Experimentation as a Shortcut
Hungarian chemist and psychiatrist Stefan Szára wanted to study LSD, but Sandoz Laboratories declined to send him samples: he lived behind the Iron Curtain, and the company feared the compound might fall into Soviet hands. Far from deterring him, this rejection directed his attention to DMT, which he synthesized in his Budapest laboratory in 1955.
Szára ingested increasing oral doses without noticing any effect. From this he shrewdly deduced that something in the digestive tract was deactivating it—an intuition that predated our understanding of the enzymatic mechanism that Amazonian cultures had learned to bypass through other means. In 1956, he tried intramuscular injection and recorded the effects firsthand. We reproduce an excerpt from his account as a historical document, not an invitation: “After 3 or 4 minutes, visual sensations began… hallucinatory images, brightly colored moving patterns… Faces looked like masks. My emotional state bordered on euphoria… Within forty-five minutes, the symptoms subsided and I was able to describe the effects.”
Self-experimentation and trials on volunteers were common scientific practice at the time, but by modern ethical standards—institutional review boards, informed consent—many of those early trials would be deemed unacceptable today. That historical context is essential when reading these accounts.
DMT Versus LSD: The Question of Duration
Szára recruited about thirty volunteers, mostly young physicians. Their reports swung between mystical euphoria (“the whole world is glowing… I feel like I am flying”) and an unsettling temptation not to return (“it would be so easy not to come back”). That ambivalence—between transcendence and distress—is precisely what enthusiastic rhetoric tends to erase.
What drew Szára to DMT was its brevity: an experience lasting under an hour, compared to the day-long journey of LSD. After leaving Hungary in the late 1950s and later emigrating to the United States, he continued studying it for decades at the National Institutes of Health in Bethesda, Maryland, where he eventually directed clinical research at the National Institute on Drug Abuse before retiring in 1991.
Other research groups corroborated his findings, including the fact that DMT required parenteral administration to be active. Curiously, almost no one else provided such nuanced psychological accounts: reports from other centers were reduced to clinical shorthand such as “anxiety, hallucinations, and perceptual distortions,” or quantified the experience on a numerical scale. This descriptive dryness was no accident; it reflected a scientific climate increasingly reluctant to take these subjective states seriously.
The Decisive Finding: A Psychedelic Made Inside Us
For years, DMT remained a pharmacological curiosity in the shadow of LSD. The picture changed once it was detected in animal—and eventually human—tissues. In 1965, Nature published the identification of DMT in human blood; subsequent research also found traces in urine and cerebrospinal fluid, and mapped the enzymatic pathways through which the body synthesizes it. DMT thus came to be recognized as an endogenous psychedelic: produced within the organism itself.
The contrast with another discovery from the era is telling. Endorphins—endogenous opioids—became a celebrated and widely accepted scientific milestone. Endogenous DMT, by contrast, arrived in the middle of a wave of institutional backlash against psychedelics, stalling research for decades. A similar category of biological discovery, yet two radically different fates dictated by the political climate of the day.
What Is It Doing There? Where the Data Ends
The question of why the body produces DMT remains unanswered today. Mid-20th-century psychiatry attempted a crude explanation by linking it to schizophrenia, a hypothesis that failed to hold up. What we do know is that DMT acts on serotonin receptors—the same systems mediating the effects of LSD, psilocybin, and mescaline—spread throughout the body, and that the brain metabolizes it remarkably fast through monoamine oxidase (MAO) enzymes. This rapid breakdown explains the fleeting nature of its effects.
One detail legitimately intrigues researchers: some studies suggest the brain does not merely tolerate DMT, but possesses active transport mechanisms to ferry it across the blood-brain barrier—the strict physiological checkpoint filtering what enters neural tissue. If verified and fully characterized, it raises a reasonable question: why would the organism expend energy doing so? Still, we must draw a clear line: the fact that the body produces and transports this molecule does not mean it has an inherently spiritual purpose, nor that baseline physiological concentrations are sufficient to alter consciousness. That is where narrative routinely outpaces evidence.
“The Spirit Molecule”: A Label, Not a Conclusion
The phrase comes from psychiatrist Rick Strassman, who in the 1990s conducted the first human clinical trials with DMT in decades at the University of New Mexico, later popularizing them in his book DMT: The Spirit Molecule (2001). Strassman proposed that DMT could reliably induce states often described as “spiritual”: a sense of timelessness, unity, the conviction that the experience is “more real than real,” and even apparent encounters with non-human entities.
It is essential to view this for what it is: a speculative hypothesis, advanced cautiously by Strassman himself and heavily debated ever since. The notion that DMT is released in massive surges at birth, death, or during near-death experiences makes for an evocative metaphor, but it lacks solid empirical support. Nor is there evidence that the pineal gland—popularly linked to the compound—produces it in physiologically meaningful amounts in humans. Just because a molecule induces experiences interpreted as spiritual does not make those experiences proof of anything external; it primarily reveals how our brain is wired to generate and assign meaning to altered states. Strassman himself emphasizes that DMT is not inherently “spiritual,” but rather a vehicle—and a vehicle can lead to terror just as easily as to ecstasy.
Critical Perspective and Harm Reduction
DMT is a prime example of how a fascinating scientific fact—that we are, in part, an internal factory for psychedelics—gets stretched into mythology. Here are several key points to keep in perspective:
- Distinguish findings from interpretation. That the body produces DMT is well established; that this “proves” the survival of consciousness after death or the existence of other dimensions is a philosophical reading, not a laboratory result.
- Be skeptical of absolute claims. Framing DMT either as “proof of the soul” or as a “meaningless metabolic artifact” oversimplifies an open scientific question.
- Historical accounts are not clinical protocols. The self-experimentation of the 1950s took place without the ethical safeguards considered indispensable today.
- Risks are real, not anecdotal. These experiences can be profoundly destabilizing psychologically, and combinations with MAO inhibitors carry dangerous interactions, including severe drug-drug interactions. Anyone facing psychological vulnerability or a family history of psychosis is at heightened risk. When health questions arise, consult a healthcare professional, not an online forum.
Psiconáutica documents and educates; it does not encourage drug use or provide instructions for consumption. For us, the interest in DMT lies in what it reveals about the interface between chemistry, consciousness, and culture—and how easy it is to cross that threshold with far more enthusiasm than evidence.
